Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01757392 · ClinicalTrials.gov registry record · Phase 2
Candin Safety & Efficacy Study for the Treatment of Warts
A Phase 2 study of Human Papilloma Virus and Warts, sponsored by Nielsen BioSciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
- 1
- Study location
NCT01757392 is a Phase 2 study of Human Papilloma Virus and Warts that has completed, run by Nielsen BioSciences. The registered enrollment target is 39 participants, below the 623-participant average among 26 other Human Papilloma Virus trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01757392, a Phase 2 study of Human Papilloma Virus and Warts, has completed, sponsored by Nielsen BioSciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this study is to determine the safety of Candin® (Candida albicans Skin Test Antigen) at a 0.3 ml dose level at up to 6 monthly injections for treating common warts (Verruca vulgaris).
Conditions Studied
Interventions
- BIOLOGICAL Candida albicans Skin Test Antigen
Study Locations (1)
Arkansas
- Johnson Dermatology - Fort Smith
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2012-09 |
| Est. Completion | 2014-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01757392
The ClinicalTrials.gov registry entry for NCT01757392 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 623-participant average among 26 other Human Papilloma Virus trials with a reported enrollment target (94% lower). The listed sponsor is Nielsen BioSciences, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Human Papilloma Virus appearing as the primary indexed condition, and to 1 intervention - of which Candida albicans Skin Test Antigen is the first listed.
NCT01757392 reports 1 study location spanning 1 distinct geographic area - top geographies include Arkansas.
Frequently Asked Questions
What is clinical trial NCT01757392 about?
NCT01757392 is a clinical study titled "Candin Safety & Efficacy Study for the Treatment of Warts". The primary objective of this study is to determine the safety of Candin® (Candida albicans Skin Test Antigen) at a 0.3 ml dose level at up to 6 monthly injections for treating common warts (Verruca vulgaris).
What is the current status of trial NCT01757392?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2012-09. Estimated completion is 2014-12.
What conditions does trial NCT01757392 study?
This clinical trial studies the following conditions: Human Papilloma Virus, Warts.
What interventions are being tested in trial NCT01757392?
The interventions under investigation include: Candida albicans Skin Test Antigen (BIOLOGICAL).
Who is sponsoring clinical trial NCT01757392?
This trial is sponsored by Nielsen BioSciences, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01757392 being conducted?
This trial has 1 study location across Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Papilloma Virus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV
RECRUITING · Phase 2
-
A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer
RECRUITING · Phase 2
-
De-Escalation Therapy for Human Papillomavirus Negative Disease
COMPLETED · Phase 2
-
Avelumab for People With Recurrent Respiratory Papillomatosis
COMPLETED · Phase 2
-
Educate and Improve Underserved Populations' Uptake and Completion of the HPV Vaccine
RECRUITING · NA
-
PopSci CHW4CervixHealth
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.